AstraZeneca to Feature Data from P-III (AMPLIFY) Study of Calquence Plus Venetoclax to Treat Chronic Lymphocytic Leukaemia at ASH 2024
Shots:
- The P-III (AMPLIFY) study assessed Calquence + venetoclax with/without obinutuzumab vs chemoimmunotherapy (fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) in treatment-naïve CLL patients without del(17p) or TP53 mutation
- Trial (median follow-up of 41mos.) depicted a 58% (with obinutuzumab) & 35% (without obinutuzumab) reduction in the disease progression or death risk; mPFS was not achieved (both arms) vs 47.6mos. OS data favored Calquence + venetoclax, but the data was immature so, its assessment is underway (2EP)
- Furthermore, 36mos. PFS rates were 83.1% & 76.5% vs 66.5% & ORRs were 92.7% & 92.8% vs 75.2% with & without obinutuzumab, respectively
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports the US FDA’s sBLA Acceptance and Priority Review of Imfinzi to Treat Muscle-Invasive Bladder Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
